Search Bar & Filters
Found 15 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating molnupiravir, a study medicine designed to stop the COVID-19 virus from multiplying, to see if it can prevent severe illness from COVID-19 more effectively than a placebo in people who are at high risk. The focus is on non-hospitalized adults with COVID-19 who have certain health conditions or factors that increase their chance of severe illness, which can require hospitalization or lead to death. Participants will be randomly assigned to receive either 800 mg of molnupiravir orally every 12 hours for 5 days a total of 10 doses or a matching placebo on the same schedule. Some participants may also receive remdesivir as standard care if clinically appropriate. This is a phase 3, double-blind, placebo-controlled study comparing molnupiravir versus placebo. During the study, participants will be monitored for up to 29 days for outcomes such as hospitalization, death, and COVID-19-related medically attended visits. Researchers will assess adverse events and discontinuation due to side effects over approximately 5 months. Other measures include tracking symptom relief, changes in virus levels, and need for medical interventions. The total participation duration covers treatment and follow-up monitoring to evaluate safety and effectiveness.
Actively Recruiting
Researchers are evaluating two forms of buprenorphine treatment for Veterans with moderate to severe opioid use disorder OUD. The study compares a long-acting injectable buprenorphine given every 28 days with the standard daily sublingual buprenorphine. This open-label, randomized trial involves 952 Veterans over a 7-year recruitment period and follows them actively for 52 weeks, with additional passive follow-up for up to 10 years. The study also examines effects on substance use, overdose rates, infectious disease status, psychiatric symptoms, housing, dental health, and cost-effectiveness. Participants are first inducted on daily sublingual buprenorphine following SAMHSA guidelines. After reaching a target dose between 4 and 32 mg within 45 days, they are randomized 11 to either continue daily sublingual doses or receive a monthly injectable buprenorphine dose of 300 mg or 100 mg if needed. Study visits occur weekly for the first month, then every two weeks up to week 52, with medication management provided at each visit. Both treatments are administered under clinical supervision with dosing adjustments as needed. Throughout the study, participants complete self-reported opioid use and provide urine samples biweekly. Researchers collect data on retention in treatment, opioid abstinence, overdose events, infectious disease testing, healthcare utilization, craving, psychiatric symptoms, criminal justice involvement, and dental quality of life. After one year of active participation, administrative records are reviewed for ongoing outcomes for up to 10 years. This comprehensive monitoring aims to provide long-term insights into treatment effectiveness and patient well-being.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of different doses of Pirtobrutinib in adults with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. Part 1 of the study focuses on participants who have received one to three prior treatments, including a covalent Bruton tyrosine kinase BTK inhibitor, while Part 2 studies treatment-nave participants with a specific genetic deletion 17p deletion. This trial is a Phase 2, open-label, randomized study sponsored by Loxo Oncology, Inc. Participants receive Pirtobrutinib orally in varying doses. In Part 1, three different doses are tested in participants with relapsed or refractory CLLSLL who have prior BTK inhibitor treatment. Part 2 evaluates Pirtobrutinib monotherapy at a standard dose in treatment-nave participants with 17p deletions. The study uses a parallel design with random assignment to treatment groups. Participants are involved for approximately three years in Part 1 and up to two years in Part 2. Researchers monitor overall response rate as the primary outcome, along with duration of response over this time. Participants must be able to swallow oral medication and have their health status regularly assessed, including physical performance scores. Safety and treatment effects are followed throughout the study period.
Actively Recruiting
Researchers are investigating the long-term effectiveness, safety, and tolerability of once-daily oral ASC30 compared to a placebo in adults with obesity or overweight and type 2 diabetes mellitus T2DM. This Phase III, global, randomized, double-blind, placebo-controlled study seeks to understand how different maintenance doses of ASC30 impact these participants over time. Participants will be randomly assigned to receive one of three doses of oral ASC30 tablets or matching placebo tablets once daily. The study compares these groups to evaluate the effects of ASC30 on weight and metabolic health over a 72-week period. Treatment is administered daily by mouth throughout the study. During participation, individuals will undergo regular assessments including measurements of body weight, blood sugar control HbA1c and fasting glucose, blood pressure, cholesterol, triglycerides, insulin levels, waist circumference, and body mass index. The main outcome is the percent change in body weight from the start to week 72. Safety and tolerability will be closely monitored, and the entire study duration spans about 72 weeks from baseline to final evaluation.
Actively Recruiting
Researchers are conducting a global Phase III clinical trial to evaluate the long-term effects of ASC30, an oral medication taken once daily, in adults with obesity or overweight who also have weight-related health conditions but do not have type 2 diabetes. The study aims to compare the efficacy, safety, and tolerability of three different maintenance doses of ASC30 against a placebo. This randomized, double-blind, placebo-controlled trial focuses on assessing body weight changes and related health measures over a lengthy period. Participants in this trial will be randomly assigned to one of four groups three groups receive different doses of ASC30 tablets daily, and one group receives matching placebo tablets daily. The treatment period is planned to last 72 weeks, during which participants will take their assigned oral tablets once a day. The study carefully monitors participants throughout the treatment phase to evaluate the effects of the medication compared to placebo. During the trial, participants will undergo regular assessments including measurements of body weight, waist circumference, blood pressure, blood glucose, cholesterol, insulin, and other metabolic markers from baseline through week 72. Researchers will also track safety and tolerability over this period. Participants can expect scheduled visits and evaluations to monitor changes in their health and response to the study medication over the roughly 1.5-year treatment duration.
Actively Recruiting
Researchers are evaluating whether adding zilovertamab vedotin to the standard treatment can help people with previously untreated diffuse large B-cell lymphoma DLBCL live longer without their cancer growing or spreading. This phase 3 randomized study compares the combination of zilovertamab vedotin with rituximab plus cyclophosphamide, doxorubicin, and prednisone R-CHP against the standard treatment of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone R-CHOP. Participants receive treatments in 21-day cycles for up to six cycles approximately four months. One group receives zilovertamab vedotin with rituximab or its biosimilar, cyclophosphamide, doxorubicin, and prednisone or similar steroids, while the other group receives rituximab or its biosimilar, cyclophosphamide, doxorubicin, vincristine, and prednisone or similar steroids. Both groups may receive up to two additional cycles of rituximab or its biosimilar as decided by the investigator. During the study, participants will have regular assessments including imaging scans and heart function tests to monitor their health and response to treatment. Researchers will measure how long participants live without disease progression, overall survival, response rates, and quality of life up to several years. Safety is monitored by tracking adverse events and treatment discontinuations. The study lasts several years, with primary outcome assessments up to about 50 months and overall survival monitored up to approximately 74 months.
Actively Recruiting
Researchers are conducting a combined phase 2b and phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effects on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This multicenter, randomized, double-blind, placebo-controlled trial is designed to provide detailed information on the drugs impact and risks. The study is divided into two parts. Part 1 phase 2b focuses on identifying the optimal dose of CSL300 compared to a placebo over 12 weeks. Part 2 phase 3 assesses the efficacy and safety of CSL300 versus placebo on cardiovascular events such as cardiovascular death or heart attack over approximately 5 years. Participants receive intravenous doses of CSL300 or placebo. The placebo matches the CSL300 product minus the active ingredient. Participants will be monitored through regular assessments including blood tests to measure markers of inflammation like high-sensitivity C-reactive protein hs-CRP, other blood components, and drug levels. The trial tracks cardiovascular events and safety outcomes over the study period. The research team will also observe changes in several blood markers related to inflammation and cardiovascular health. The total follow-up may last up to about five years to fully capture long-term effects and safety.
Actively Recruiting
This research aims to compare the impact of Exposure and Response Prevention ERP therapy versus a stress management training control on Veterans with Obsessive Compulsive Disorder OCD, including those with both OCD and posttraumatic stress disorder PTSD. The study will evaluate how these treatments affect Veterans functioning, quality of life, and OCD symptoms. Additionally, the study will explore the potential for implementing ERP in Veterans Affairs VA mental health settings through mixed-methods evaluation. Participants will be randomly assigned to receive either 16 weekly sessions of ERP or 16 weekly sessions of stress management training, both delivered via video telehealth VTH. ERP sessions, lasting 90 minutes each, involve psychoeducation, assessment, exposures to feared situations, and homework assignments focused on coping with OCD triggers. Stress management training includes psychoeducation and sessions teaching relaxation and coping skills. Assessments will be conducted after treatment and six months later. ERP participants will also provide feedback on treatment satisfaction and participate in qualitative interviews. Veterans will be involved in completing assessments of their work and social adjustment, quality of life, and OCD symptoms at baseline, post-treatment, and six months post-treatment. Researchers will collect data on treatment effects and implementation potential. Therapy sessions will be audio-recorded. The total participation lasts through treatment and follow-up visits up to six months after treatment completion.
Actively Recruiting
This research aims to compare two treatment approaches for men with intermediate risk localized prostate cancer. The study evaluates proton beam radiation therapy alone versus proton therapy combined with androgen suppression therapy. The goal is to better understand the benefits and potential side effects of adding androgen suppression to radiation treatment. Participants receive one of two treatments either hypofractionated proton radiation therapy alone, given in 28 treatments over about 5.5 to 6.5 weeks, or proton therapy combined with androgen suppression therapy started 8 to 10 weeks before radiation and continued for about six months. Radiation options also include high dose IMRT alone or a combination of brachytherapy and IMRT, depending on the treatment arm. During the study, participants will be monitored regularly for side effects and treatment outcomes. Researchers will assess morbidity outcomes after at least three years of follow-up, along with toxicity levels, quality of life, biochemical failure rates, clinical failure, survival, and hormone levels over a five-year period. The study involves multiple assessments to gather data on the effects of the treatments on prostate cancer and patient well-being.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating a bivalent vaccine candidate designed to protect adults aged 60 years and older against Respiratory Syncytial Virus RSV and Human Metapneumovirus HMPV. This Phase 12, randomized, observer-blind, placebo-controlled study involves about 2400 participants and aims to assess the vaccines ability to trigger immune responses and monitor its safety. While several RSV vaccines are approved, there is currently no vaccine for preventing HMPV in older adults. Participants will be assigned to one of 11 groups, receiving different doses of the RSVHMPV vaccine, placebo, or one of four control vaccines. The study includes six dose levels of the RSVHMPV vaccine with predefined antigen ratios. Each participant will be followed for approximately 12 months to allow comprehensive evaluation. The study is conducted across multiple centers and uses a parallel group design. During the study, participants will have blood samples taken at baseline, Day 29, and at 3, 6, 9, and 12 months to measure neutralizing antibodies and immunoglobulin G concentrations against RSV and HMPV. Safety will be monitored through reporting of adverse events shortly after vaccination, for several days post-vaccination, and up to six months or throughout the 12-month study period. Biological tests and medical assessments will also be performed to ensure participant safety and collect detailed data on immune response.
1-10 of 15
1